Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7381427 | ACLARIS | Seborrheic keratosis treatment |
Jun, 2022
(1 year, 10 months ago) | |
US10098910 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US9980983 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US10493103 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US10729720 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Apr, 2035
(10 years from now) | |
US9675639 | ACLARIS | Peroxide formulations and methods and applicators for using the same |
Jul, 2035
(11 years from now) |
Eskata is owned by Aclaris.
Eskata contains Hydrogen Peroxide.
Eskata has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Eskata are:
Eskata was authorised for market use on 14 December, 2017.
Eskata is available in solution;topical dosage forms.
Eskata can be used as treatment of seborrheic keratoses that are raised.
The generics of Eskata are possible to be released after 04 July, 2035.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 14, 2020 |
Drugs and Companies using
HYDROGEN PEROXIDE ingredient